EDIT vs IR
Editas Medicine Inc (EDIT) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported IR revenue for 2024-12-31 was $7.24B. Net income was $846.3M. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. IR currently screens at market cap $28.27B and trailing P/E 48.8.
EDIT currently screens at market cap $375.2M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the EDIT and IR stock pages for the full models.
Not investment advice.